{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:53:24Z","timestamp":1791899604606,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013915","name":"Sarnoff Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorable efficacy and tolerability profile compared to previous generations of EGFR inhibitors. However, it can cause uncommon, yet serious, cardiovascular adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case Presentation<\/jats:title>\n                <jats:p>We present the case of a 63-year-old man with EGFR-mutated NSCLC treated with osimertinib who developed new-onset non-ischemic cardiomyopathy with biventricular dysfunction and heart failure in the context of an enlarging pericardial effusion. For the first time, we demonstrate cardiac MR imaging findings associated with osimertinib-associated cardiomyopathy, including focal late gadolinium enhancement and myocardial edema. The patient\u2019s biventricular function normalized after initiation of goal-directed medical therapy for heart failure and holding osimertinib. The patient was subsequently started on afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), without recurrence of cardiomyopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case highlights the need to better understand osimertinib-induced cardiotoxicity and strategies to optimize oncologic care in patients who develop severe cardiac toxicities from cancer therapy. It further underlines the importance of specialized multidisciplinary care of cancer patients who develop cardiotoxicities to optimize their oncologic outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-023-00190-1","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:02:32Z","timestamp":1698735752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Karishma","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie Y.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire K.","family":"Mulvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"2","key":"190_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced cardiotoxicity: a retrospective review of the FDA adverse events reporting System (FAERS). JACC CardioOncol. 2019;1(2):172\u20138.","journal-title":"JACC CardioOncol"},{"issue":"39","key":"190_CR2","doi-asserted-by":"publisher","first-page":"e22301","DOI":"10.1097\/MD.0000000000022301","volume":"99","author":"S Shinomiya","year":"2020","unstructured":"Shinomiya S, Kaira K, Yamaguchi O, Ishikawa K, Kagamu H. Osimertinib induced cardiomyopathy. Medicine. 2020;99(39):e22301.","journal-title":"Medicine"},{"issue":"16","key":"190_CR3","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.2169\/internalmedicine.8344-16","volume":"56","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ichihara E, Kano H, et al. Congestive Heart Failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell Lung cancer (NSCLC). Intern Med. 2017;56(16):8344\u201316.","journal-title":"Intern Med"},{"issue":"10","key":"190_CR4","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jtho.2017.05.016","volume":"12","author":"T Oyakawa","year":"2017","unstructured":"Oyakawa T, Nakashima K, Naito T. Cardiac dysfunction caused by osimertinib. J Thorac Oncol. 2017;12(10):e159\u201360.","journal-title":"J Thorac Oncol"},{"key":"190_CR5","first-page":"52","volume":"6","author":"M Reale","year":"2018","unstructured":"Reale M, Bianco M, Tabbo F, et al. Osimertinib-induced cardiac dysfunction in EGFR-mutated Lung cancer: a case series of five patients. Am J Cancer Case Reports. 2018;6:52\u201360.","journal-title":"Am J Cancer Case Reports"},{"issue":"4","key":"190_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","volume":"2","author":"S Patel","year":"2020","unstructured":"Patel S, Brown S-A, Kubusek J, et al. Osimertinib-induced cardiomyopathy. JACC Case Reports. 2020;2(4):641\u20135.","journal-title":"JACC Case Reports"},{"issue":"4","key":"190_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","volume":"39","author":"M Ewer","year":"2021","unstructured":"Ewer M, Tekumalla S, Walding A, Atuah K. Cardiac Safety of Osimertinib: a review of data. J Clin Oncol. 2021;39(4):328\u201337.","journal-title":"J Clin Oncol"},{"issue":"1","key":"190_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10637-019-00808-1","volume":"38","author":"T Kawamura","year":"2020","unstructured":"Kawamura T, Kenmotsu H, Kobayashi H, et al. Negative impact of malignant effusion on osimertinib treatment for non-small cell Lung cancer harboring EGFR mutation. Invest New Drugs. 2020;38(1):194\u2013201. https:\/\/doi.org\/10.1007\/s10637-019-00808-1.","journal-title":"Invest New Drugs"},{"issue":"5","key":"190_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cllc.2011.06.004","volume":"12","author":"K Masago","year":"2011","unstructured":"Masago K, Togashi Y, Fukudo M, et al. Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell Lung cancer with pleural effusion. Clin Lung Cancer. 2011;12(5):307\u201312. https:\/\/doi.org\/10.1016\/j.cllc.2011.06.004.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"190_CR10","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s12350-018-1293-9","volume":"25","author":"A L\u00f6ffler","year":"2018","unstructured":"L\u00f6ffler A, Salerno M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol. 2018;25(6):2148\u201358. https:\/\/doi.org\/10.1007\/s12350-018-1293-9.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"190_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","volume":"2","author":"S Patel","year":"2020","unstructured":"Patel S, Brown S-AN, Kubusek J, et al. Osimertinib-induced cardiomyopathy. JACC Case Reports. 2020;2(4):641\u20135.","journal-title":"JACC Case Reports"},{"issue":"2","key":"190_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/medicina58020312","volume":"58","author":"A Fukuo","year":"2022","unstructured":"Fukuo A, Imamura T, Onoda H, Kinugawa K. Successful management of osimertinib-induced Heart Failure. Medicina. 2022;58(2):312.","journal-title":"Medicina"},{"issue":"9","key":"190_CR13","doi-asserted-by":"publisher","first-page":"e6279","DOI":"10.1002\/ccr3.6279","volume":"10","author":"Y Fukuda","year":"2022","unstructured":"Fukuda Y, Kawa Y, Nonaka A, Shiotani H. Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: a case report. Clin Case Reports. 2022;10(9):e6279.","journal-title":"Clin Case Reports"},{"issue":"1","key":"190_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-015-0006-7","volume":"1","author":"M Ewer","year":"2015","unstructured":"Ewer M, Patel K, O\u2019Brien D, Lorence R. Cardiac safety of afatinib: a review of data from clinical trials. Cardio-Oncology. 2015;1(1):3.","journal-title":"Cardio-Oncology"}],"updated-by":[{"DOI":"10.1186\/s40959-023-00195-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000}}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-023-00190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:06:22Z","timestamp":1701255982000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-023-00190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1186\/s40959-023-00190-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40959-023-00195-w","asserted-by":"object"}]},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40959-023-00195-w","URL":"https:\/\/doi.org\/10.1186\/s40959-023-00195-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained from patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}